DIAGONAL BIO AB

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, DIAGONAL BIO AB had revenue of €0 and net profit of -€234.42k

(EUR)	June 2025	YoY
Revenue	0	-
Gross profit	24.77k	-
Net profit	-234.42k	-
EBITDA	-206.69k	-

Fundamentals

Metric	Value
Market capitalization	€1.82m
Number of shares	1.39bn
52-week high/low	€0.00144 - €0.00108
Dividends	No
Beta	-1.85
P/E ratio	-0.36
PEG ratio	0.00
P/B ratio	0.16
P/S ratio	325.78

Company profile

Diagonal Bio AB operates as a biotechnology company in Sweden. It is involved in developing the Panviral platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria, and fungi. The company was founded in 2020 and is headquartered in Lund, Sweden.